MTX-induced white matter changes are associated with polymorphisms of methionine metabolism |
| |
| Authors: | Linnebank M Pels H Kleczar N Farmand S Fliessbach K Urbach H Orlopp K Klockgether T Schmidt-Wolf I G H Schlegel U |
| |
| Affiliation: | Department of Neurology, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. Michael.Linnebank@ukb.uni-bonn.de |
| |
| Abstract: | Methotrexate (MTX) is a folate antagonist inhibiting nucleic acid and methionine synthesis. Methionine is necessary for CNS myelination. In 42 patients with primary CNS lymphoma (PCNSL) treated with a systemic and intraventricular high-dose MTX-based polychemotherapy, the presence of a risk haplotype defined by polymorphisms influencing methionine metabolism referred a relative risk for CNS white matter changes of 4.7 (p = 0.001). The authors conclude that methionine metabolism influences MTX neurotoxicity. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
